 |
Samsung BioLogics (photo = Yonhap news) |
[Alpha Biz= Reporter Paul Lee] Mirae Asset Securities predicted on the 25th that Samsung BioLogics has a high possibility of mid- to long-term benefits through consignment development production (CDMO).
Mirae Asset Securities made the announcement based on Samsung BioLogics' recent performance conference call, "We are inquiring about CDMO orders from more various customers."
Mirae Asset Securities added that large pharmaceutical companies are expressing concern about the supply chain, and many CDMO companies see it as an opportunity.
Mirae Asset Securities said on the previous day that it recorded sales of 669.5 billion won and operating profit of 232.7 billion won in the first quarter. Its subsidiary Samsung Bioepis achieved sales of 280.1 billion won and operating profit of 38.1 billion won.
Mirae Asset Securities maintained an estimate of Samsung Biologics' sales of 3.32 trillion won and operating profit of 1.2279 trillion won this year.
The investment opinion and target price of Samsung BioLogics remained 'buy' and 1.1 million won.
Alphabiz Reporter Kim SangJin(hoondork1977@alphabiz.co.kr)
